Pasithea Wins FDA Rare Pediatric Disease Status For PAS-004 To Treat Neurofibromatosis Type 1

Pasithea Therapeutics received FDA Rare Pediatric Disease Designation for PAS-004 in Neurofibromatosis Type 1 (NF1). The designation is a regulatory positive for the program and may enhance the drug's development and commercial optionality. The news is favorable for KTTA, but it is a limited near-term catalyst and likely to have modest stock impact.

Analysis

Pasithea Therapeutics received FDA Rare Pediatric Disease Designation for PAS-004 in Neurofibromatosis Type 1 (NF1). The designation is a regulatory positive for the program and may enhance the drug's development and commercial optionality. The news is favorable for KTTA, but it is a limited near-term catalyst and likely to have modest stock impact.